HomeRGLS • NASDAQ
add
Regulus Therapeutics Inc
Previous close
$1.72
Day range
$1.63 - $1.84
Year range
$0.83 - $2.90
Market cap
117.91M USD
Avg Volume
1.72M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | -19.51M | -59.75% |
Net income | -12.79M | -58.68% |
Net profit margin | — | — |
Earnings per share | -0.20 | 50.00% |
EBITDA | -13.66M | -66.09% |
Effective tax rate | 0.00% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 75.78M | 218.83% |
Total assets | 84.18M | 173.76% |
Total liabilities | 7.77M | -18.72% |
Total equity | 76.41M | — |
Shares outstanding | 66.24M | — |
Price to book | 1.47 | — |
Return on assets | -38.62% | — |
Return on capital | -41.53% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -12.79M | -58.68% |
Cash from operations | -11.84M | -93.39% |
Cash from investing | 24.00M | 386.62% |
Cash from financing | 0.00 | 100.00% |
Net change in cash | 12.16M | 688.33% |
Free cash flow | -7.24M | -119.86% |
About
Regulus Therapeutics Inc. is a clinical stage biopharmaceutical company focused on the development of first-in-class drugs that target microRNAs to treat a broad range of diseases. Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. Wikipedia
Founded
Sep 2007
Website
Employees
34
